Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Current Liabilities (2016 - 2025)

Avalo Therapeutics' Total Current Liabilities history spans 12 years, with the latest figure at $12.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 85.92% year-over-year to $12.9 million; the TTM value through Dec 2025 reached $12.9 million, up 85.92%, while the annual FY2025 figure was $12.9 million, 85.92% up from the prior year.
  • Total Current Liabilities reached $12.9 million in Q4 2025 per AVTX's latest filing, up from $8.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $215.7 million in Q1 2024 to a low of $4.6 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $31.6 million, with a median of $18.6 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: surged 910.39% in 2024, then plummeted 97.4% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $19.9 million in 2021, then grew by 11.19% to $22.1 million in 2022, then plummeted by 79.12% to $4.6 million in 2023, then skyrocketed by 50.71% to $7.0 million in 2024, then surged by 85.92% to $12.9 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Total Current Liabilities are $12.9 million (Q4 2025), $8.0 million (Q3 2025), and $9.3 million (Q2 2025).